Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Hisse Senetlerindeki Sıralama #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Hisse Fiyatı
$1,133.97
Son senkronizasyon: 2026-09-15
Piyasa Değeri
$1.068T
Değişim (1 gün)
-0.39%
Değişim (1 yıl)
48.29%
Ülke
US
Ticaret Eli Lilly and Company (LLY)

Kategori

Eli Lilly and Company (LLY) için temettü geçmişi
Eli Lilly and Company (hisse sembolü: LLY) toplam 215 temettü ödemesi yaptı.
Tüm temettülerin toplamı (hisse bölünmeleriyle ayarlanmış): $72.49
Temettü verimi (TTM): 0.0059
Eli Lilly and Company (LLY) için 1972 ile 2026 arasındaki temettü ödemeleri
Yıllık temettü ödemeleri
Yıl Temettü (hisse bölünmesiyle ayarlanmış) Değiştir
2026 (TTM) $1.73 -71.17%
2025 $6.00 15.38%
2024 $5.20 15.04%
2023 $4.52 15.31%
2022 $3.92 15.29%
2021 $3.40 14.86%
2020 $2.96 14.73%
2019 $2.58 14.67%
2018 $2.25 8.17%
2017 $2.08 1.96%
2016 $2.04 2.00%
2015 $2.00 2.04%
2014 $1.96 0.00%
2013 $1.96 0.00%
2012 $1.96 0.00%
2011 $1.96 0.00%
2010 $1.96 0.00%
2009 $1.96 4.26%
2008 $1.88 10.59%
2007 $1.70 6.25%
2006 $1.60 5.26%
2005 $1.52 7.04%
2004 $1.42 5.97%
2003 $1.34 8.06%
2002 $1.24 10.71%
2001 $1.12 7.69%
2000 $1.04 13.04%
1999 $0.92 15.00%
1998 $0.8 8.11%
1997 $0.74 8.00%
1996 $0.6852 4.58%
1995 $0.6552 4.80%
1994 $0.6252 3.30%
1993 $0.6052 10.04%
1992 $0.55 10.00%
1991 $0.5 21.95%
1990 $0.41 21.55%
1989 $0.3373 17.28%
1988 $0.2876 15.04%
1987 $0.25 11.01%
1986 $0.2252 12.60%
1985 $0.2 7.58%
1984 $0.1859 8.21%
1983 $0.1718 5.79%
1982 $0.1624 13.09%
1981 $0.1436 4.51%
1980 $0.1374 12.81%
1979 $0.1218 18.14%
1978 $0.1031 16.10%
1977 $0.0888 13.55%
1976 $0.0782 13.66%
1975 $0.0688 13.53%
1974 $0.0606 22.67%
1973 $0.0494 116.67%
1972 $0.0228 0.00%
Tüm temettü ödemelerinin listesi
Yıl Temettü Değiştir
2026 (TTM) $1.73 -71.17%
2025 $6.00 15.38%
2024 $5.20 15.04%
2023 $4.52 15.31%
2022 $3.92 15.29%
2021 $3.40 14.86%
2020 $2.96 14.73%
2019 $2.58 14.67%
2018 $2.25 8.17%
2017 $2.08 1.96%
2016 $2.04 2.00%
2015 $2.00 2.04%
2014 $1.96 0.00%
2013 $1.96 0.00%
2012 $1.96 0.00%
2011 $1.96 0.00%
2010 $1.96 0.00%
2009 $1.96 4.26%
2008 $1.88 10.59%
2007 $1.70 6.25%
2006 $1.60 5.26%
2005 $1.52 7.04%
2004 $1.42 5.97%
2003 $1.34 8.06%
2002 $1.24 10.71%
2001 $1.12 7.69%
2000 $1.04 13.04%
1999 $0.92 15.00%
1998 $0.8 -37.50%
1997 $1.28 -6.57%
1996 $1.37 -47.71%
1995 $2.62 4.80%
1994 $2.50 3.31%
1993 $2.42 10.00%
1992 $2.20 10.00%
1991 $2.00 21.95%
1990 $1.64 -2.73%
1989 $1.69 -26.70%
1988 $2.30 15.00%
1987 $2.00 11.11%
1986 $1.80 -43.75%
1985 $3.20 7.56%
1984 $2.98 8.18%
1983 $2.75 5.77%
1982 $2.60 13.04%
1981 $2.30 4.55%
1980 $2.20 12.82%
1979 $1.95 18.18%
1978 $1.65 16.20%
1977 $1.42 13.60%
1976 $1.25 13.64%
1975 $1.10 13.40%
1974 $0.97 22.47%
1973 $0.792 117.58%
1972 $0.364 0.00%
Benzer şirketler veya rakipler için temettü ödemeleri
Şirket Temettü ödemesi sayısı Ülke
225.00%
US
53.00%
US
33.00%
CH
223.00%
US
29.00%
CH